AstraZeneca's Evusheld therapy provides protection against COVID-19 for at least 6 months
Covid vaccine
A new study has shown that AstraZeneca's Evusheld therapy provides protection against COVID-19 for at least six months.
The antibody cocktail produced by the British-Swedish multinational pharmaceutical and biotechnology company offers 83 per cent protection against the novel virus.
Made from a combination of two antibodies, the AZD7442 treatment had been undergoing final clinical trials to assess its safety and efficacy.
In an earlier readout of the late-stage PROVENT trial in August, had previously been shown to confer 77 per cent protection against symptomatic illness after three months.
The data is encouraging as potential additional protection for people who do not respond well to vaccines, such as cancer patients.
)
The Royals enter the Doctor Who universe: King Charles and Queen Camilla beam into Commonwealth Games in TARDIS
)
Trump's battleship fantasy gets a $275 billion reality check
)
'I was almost trafficked in Paris,' says Australian woman, shares terrifying ordeal - 'I am on the black market'
)
After NEET protests, CJP holds crucial strategy meet in Maharashtra to chart national expansion
)
France offers deal for 114 Rafale fighter jets, with 94 to be made in India
)
Ukrainian astronomers see gargantuan objects dashing at 39,600 kmph on the Moon - 'They can reach Earth in 20 minutes'
)
Pakistan inks defence pact with Somalia amid Houthi threat in Bab al-Mandab | Gravitas
)
Cabinet approves ₹23,731 crore GOBARdhan scheme to boost compressed biogas production
)
India avoids higher US tariff, secures lower 10% rate. Here's how
)
Something is lurking under the ships in Strait of Hormuz, and could spawn a 'biological apocalypse'
)
Lightning bolt strikes football field in Thailand, killing a player during a match
)
Salman Khan and Aamir Khan pay heartfelt tribute to late actor Pradeep Rawat
)
At least 30 Yemeni troops killed in Houthi missile and drone attacks; toll may go up
)
Mark Zuckerberg apologises to Indian government over harmful content, platform errors amid PM video row
&im=FitAndFill=(700,400))
Who is Shreya Kalra? Meet the social media star who lifted the Lock Upp 2 trophy
)
High-profile tennis club kills its long-term resident geese for pooping on the court
)
'Monisha beta, read civics': Anupamaa star Rupali Ganguly slammed for wishing PM Modi were a 'dictator'
)
The genetic roots of Tamils: 75,000 DNA markers decoded in latest study of Sangam-era settlement
)
Netanyahu reignites tensions with Lebanon strikes, Iran threatens to hit Gulf states | Gravitas
)
Squadron Leader Bhawana Kanth scripts history as Indian Air Force gets its first woman ‘Top Gun’ pilot
)
'I would like to support...': Sonam Wangchuk reveals if he will join Jharkhand student protesters in Ranchi
)
Trump says Iranian school bombing photos could be AI-generated - 'I don’t think...'
)
'Dhoni Made Fleming Great': Panesar says ECB made the wrong choice for England Test coach
)
Ex top Pakistan official blames economic woes on China: Here's how CPEC became a failure
)
Now we know that the Reflecting Pool sealant was indeed knifed, and who did it
&im=FitAndFill=(700,400))
From Jos Buttler to Kieron Pollard, 5 highest run-scorers in T20 cricket
)
When Salman Khan wouldn’t let Pradeep Rawat go home for six months: ‘I’d eat there, sleep there, work out there'
)
India cuts timeline to remove unlawful AI content from 36 to 3 hours. What are the new rules?
&im=FitAndFill=(700,400))
Why Russian tanks are much lighter compared to US tanks
)
Who is Abhay Kumar Tiwari? The alleged mastermind of Jharkhand exam paper leaks
)
Secret weapon test blamed for US plane crash that killed four | Gravitas
According to AstraZeneca Executive Vice President Mene Pangalos,"These new data add to the growing body of evidence supporting AZD7442's potential ... We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 as quickly as possible."
It comes after Chief executive Pascal Soriot had revealed that the drugs company got positive results from a trial of a treatment for Covid-19 symptoms, which is being produced alongside its vaccine.
The pharmaceutical giant has sold its vaccine at cost during the pandemic in contrast to rivals including US giant Pfizer.
In India, AstraZeneca's shot is sold under a licensed version called Covishield. It is made by the Serum Institute of India (SII), the world's biggest vaccine maker.
It accounts for nearly 90 per cent of the 1.24 billion doses administered in India.
(With inputs from agencies)